Shree Ganesh Bio-Tech
0.47
-0.01(-2.08%)
Market Cap₹18.70 Cr
PE Ratio-48.00
IndustryHealthcare
Company Performance:
1D-2.08%
1M-9.62%
6M-17.54%
1Y-40.51%
5Y-93.14%
View Company Insightsright
More news about Shree Ganesh Bio-Tech
04May 26
Shree Ganesh Bio-Tech (India) Limited Schedules Board Meeting on May 14, 2026 to Approve FY26 Audited Financial Results
Shree Ganesh Bio-Tech (India) Limited has informed stock exchanges of a board meeting to be held on May 14, 2026, under Regulation 29 of SEBI (LODR) Regulations, 2015. The meeting's primary agenda is to approve the audited standalone financial results for the quarter and year ended March 31, 2026, along with auditor reports. The intimation was filed with BSE Limited, The Calcutta Stock Exchange Ltd, and Metropolitan Stock Exchange of India Limited, and was signed by Director Aman Patel on May 4, 2026.
 no imag found
07Apr 26
Shree Ganesh Bio-Tech Submits Q4FY26 SEBI Compliance Certificate for Share Dematerialization
Shree Ganesh Bio-Tech (India) Limited submitted its Q4FY26 compliance certificate under SEBI Regulation 74(5) for share dematerialization activities. The certificate, issued by Satellite Corporate Services Private Limited on 06.04.2026, confirms no physical share certificates were received for dematerialization during the quarter ended 31st March 2026, fulfilling mandatory regulatory requirements.
 no imag found
29Jan 26
Shree Ganesh Bio-Tech (India) Limited Reports Q3FY26 Financial Results
Shree Ganesh Bio-Tech (India) Limited reported Q3FY26 results with revenue from operations of ₹69.81 lakh and net profit of ₹32.23 lakh for the quarter ended December 31, 2025. For the nine-month period, the company achieved revenue of ₹284.92 lakh and net profit of ₹66.34 lakh. The results were approved by the Board of Directors on January 29, 2026, following review by the Audit Committee and limited review by statutory auditors.
 no imag found
08Nov 25
Shree Ganesh Bio-Tech Reports Revenue Decline in Q2 FY2026
Shree Ganesh Bio-Tech (India) Limited announced unaudited financial results for Q2 and H1 FY2026. Revenue from operations decreased by 61.32% to Rs. 76.74 lakhs in Q2 FY2026 from Rs. 198.40 lakhs in Q2 FY2025. Net profit after tax fell by 95.64% to Rs. 1.41 lakhs in Q2 FY2026 from Rs. 32.34 lakhs in Q2 FY2025. For H1 FY2026, revenue dropped 61.17% to Rs. 215.10 lakhs, while profit before tax decreased by 39.22% to Rs. 34.11 lakhs compared to H1 FY2025. Other income increased to Rs. 41.01 lakhs in Q2 FY2026 from Rs. 30.29 lakhs in Q2 FY2025. The company's total assets stood at Rs. 6,513.75 lakhs with an equity base of Rs. 6,359.70 lakhs as of September 30, 2025.
 no imag found
25Jul 25
Shree Ganesh Biotech Reports 37.5% Jump in Net Profit for Quarter Ended June
Shree Ganesh Bio-Tech (India) Limited reported a net profit of Rs. 32.70 lacs for Q1, up 37.5% year-over-year, despite a 61.1% decline in revenue to Rs. 138.36 lacs. Total income fell 54.2% to Rs. 179.89 lacs, while expenses were reduced by 60.1% to Rs. 147.19 lacs. The company maintained its EPS at Rs. 0.01. The Board of Directors approved these unaudited financial results on July 25.
 no imag found
Shree Ganesh Bio-Tech
0.47
-0.01
(-2.08%)
1 Year Returns:-40.51%
Industry Peers
Anthem Biosciences
908.45
(-3.65%)
Advanced Enzyme Tech
287.85
(+0.05%)
CCME Global
33.07
(+4.98%)
Vivo Bio Tech
16.83
(-2.09%)